Saturn V Capital Management LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Saturn V Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$10.32 - $14.76 $1.98 Million - $2.84 Million	-192,267 Reduced 75.38%	62,793 $710 Million
Q1 2025 May 15, 2025	SELL	$7.4 - $12.6 $2.23 Million - $3.8 Million	-301,429 Reduced 54.17%	255,060 $2.94 Billion
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $5.41 Million - $8.8 Million	-571,989 Reduced 50.69%	556,489 $6.44 Billion
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $3.24 Million - $3.92 Million	-313,474 Reduced 21.74%	1,128,478 $13.3 Billion
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $4.05 Million - $5.86 Million	-365,611 Reduced 20.23%	1,441,952 $17.1 Billion

Q4 2023 Feb 14, 2024	SELL	$7.58 - $12.25 $20,337 - $32,866	-2,683 Reduced 0.15%	1,807,563 $22.1 Billion
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $3.56 Million - $4.52 Million	397,910 Added 28.17%	1,810,246 $17.4 Billion
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $2.24 Million - $3.07 Million	290,354 Added 25.88%	1,412,336 $12.7 Billion
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $2.53 Million - $3.37 Million	402,045 Added 55.84%	1,121,982 $8.82 Billion
Q4 2022 Feb 09, 2023	BUY	$4.2 - $14.24 $3.02 Million - $10.3 Million	719,937 New	719,937 $6.7 Billion

155

57.9M

1.21M

865K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $328M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Saturn V Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Saturn V Capital Management LLC with notifications on news.